D. Castéra

Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin

Jean-Louis Pujol, Jean-Luc Breton, R. Gervais et al. · Annals of Oncology · 2005 · 131 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF

Bruno Chauffert, L. Feuvret, Franck Bonnetain et al. · Annals of Oncology · 2014 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results

Jacques Rouëssé, Brigitte De La Lande, F. Bertheault-Cvitkovic et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 75 citations

Medicine, Oncology, Radiation Oncology +16

Multicenter phase II–III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients

J.L. Misset, P Vennin, P. Chollet et al. · Annals of Oncology · 2001 · 35 citations · Full text

Medicine, Gynecology, Oncology +12

Prognostic value of health‐related quality of life for death risk stratification in patients with unresectable glioblastoma

Brice Paquette, Déwi Vernerey, Bruno Chauffert et al. · Cancer Medicine · 2016 · 19 citations · Full text

Medicine, Biostatistics, Oncology +15